Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Krebs Biochemicals & Industries Limited is an Indian specialty pharmaceutical manufacturer focused on active pharmaceutical ingredients (APIs) and intermediates. The company operates in a highly competitive generic drug manufacturing space with significant margin pressure, evidenced by an 87% gross margin collapsing to deeply negative operating margins of -50%, indicating severe operational inefficiencies or restructuring costs. The stock has declined 29% over the past year amid revenue contraction of 14% and deteriorating cash flow generation.
Krebs generates revenue by manufacturing and selling APIs and intermediates to generic drug companies in India and export markets. The business model relies on chemical synthesis capabilities, regulatory compliance (GMP certifications), and cost-competitive manufacturing. The 87% gross margin suggests strong pricing power or low direct material costs, but the -50% operating margin indicates unsustainable overhead structure, potential idle capacity, or one-time restructuring charges. Pricing power in API manufacturing is typically limited due to commoditization, with competition from Chinese and Indian manufacturers driving margin compression.
New API product approvals and regulatory certifications (USFDA, EUGMP) that expand addressable market
Raw material cost fluctuations, particularly key chemical intermediates sourced from China
Capacity utilization rates and ability to secure long-term supply contracts with generic manufacturers
Working capital management and cash burn rate given negative operating cash flow of $100M
Restructuring progress and path to operating profitability
Commoditization of generic API manufacturing with intense price competition from Chinese manufacturers benefiting from scale economies and vertical integration
Regulatory compliance costs escalating with stricter USFDA and EUGMP standards, requiring continuous capex investment that the company cannot currently afford
Environmental regulations in India tightening on chemical manufacturing, potentially requiring costly effluent treatment upgrades
Large integrated pharmaceutical companies backward integrating into API production, reducing addressable market for independent API suppliers
Chinese API manufacturers with 30-40% cost advantages due to scale, vertical integration, and government support capturing market share
Customer concentration risk if reliant on few large generic manufacturers who possess significant bargaining power
Negative equity position (debt/equity of -1.39) indicates liabilities exceed assets, suggesting potential insolvency risk without restructuring or capital injection
Current ratio of 0.09x indicates severe short-term liquidity crisis with current liabilities 11x current assets, raising going concern questions
Negative operating cash flow of $100M with minimal capex suggests cash is being consumed by working capital and operating losses, not growth investment
Potential covenant breaches on existing debt facilities given deteriorating financial performance could trigger acceleration clauses
moderate - Pharmaceutical demand is relatively non-cyclical as healthcare spending persists through economic cycles, but generic drug pricing and volume growth can be affected by healthcare budget constraints, insurance reimbursement rates, and hospital utilization patterns. Export demand to developed markets (US, Europe) is influenced by healthcare spending trends and generic drug adoption rates.
Rising interest rates negatively impact Krebs through multiple channels: (1) higher financing costs on working capital facilities given negative cash flow, (2) increased discount rates compress valuation multiples for unprofitable growth companies, (3) stronger USD (typically correlated with rising US rates) makes Indian exports less competitive but reduces rupee cost of imported raw materials. The negative debt/equity ratio of -1.39 suggests negative equity, making the company highly vulnerable to refinancing risk.
Critical - With negative operating cash flow of $100M, current ratio of 0.09x, and negative equity, Krebs faces severe liquidity constraints and likely depends on continued credit facility access or equity infusions. Tightening credit conditions or rising borrowing costs could trigger a liquidity crisis. The company's ability to secure working capital financing for raw material purchases and fund ongoing operations is essential for survival.
Speculative/distressed - The company's negative profitability, severe liquidity constraints, and 29% one-year decline attract primarily distressed investors, turnaround specialists, or high-risk speculators betting on restructuring success. Not suitable for value investors (negative book value), growth investors (revenue declining 14%), or dividend investors (no cash generation). The investment thesis would center on survival probability and potential recovery to breakeven operations.
high - Small-cap pharmaceutical stock with severe financial distress, negative cash flow, and liquidity crisis exhibits extreme volatility. Any news on debt restructuring, regulatory actions, customer contract wins/losses, or liquidity events would drive sharp price movements. The -16.5% three-month return and -29.3% one-year return demonstrate high downside volatility, and the stock likely trades with elevated beta above 1.5x.
